#Tetra bio pharma stock trial
#Tetra bio pharma stock license

Further, there have been numerous news reports recently of drug makers exiting the opioid business, however for patients suffering from uncontrolled pain, this news does not provide them with an alternative to alleviate their pain. The approval by the DEA is a formality as the amendment does not modify the amount of controlled substance at the clinical site.

#Tetra bio pharma stock license

Once the Schedule I license is approved, a process that usually takes a couple of weeks, the amended protocol will enhance the recruitment rate, thereby accelerating the study conduct. It will facilitate the recruitment of patients who can benefit from QIXLEEF™ to treat their breakthrough pain as it broadens the pool of qualified patients. Guy Chamberland, CEO and CRO commented, 'The amended protocol allows QIXLEEF™ to be studied against three types of immediate release oral opioids instead of just one.

When pharmaceutical grade cannabis is vaporized rather than smoked, the beneficial components can be inhaled without the generation of smoke and combusted by-products.ĭr. The medication is inhaled through a Class II medical vaporizer. QIXLEEF™ is the Company's inhaled proprietary drug formulation which has a fixed ratio of THC and CBD. The amended protocol will be implemented at the clinical site upon approval of the Drug Enforcement Administration (DEA) and amendment of the study-specific Schedule I license. Well-designed clinical evidence is required to demonstrate to physicians that QIXLEEF™ can be an alternative to the class of immediate release oral opioids. This amendment will allow the Company to demonstrate the potential efficacy of QIXLEEF™ against a class of immediate relief oral opioids. The approved amended protocol opens the recruitment to cancer patients with breakthrough pain who are treated with either oral morphine sulfate immediate release, oral hydromorphone immediate release, or oral oxycodone immediate release. The initial protocol was assessing a direct safety and efficacy comparison between QIXLEEF™ and oral morphine sulfate immediate release on the onset of pain relief in this population.

#Tetra bio pharma stock trial

The REBORN1© trial is a head-to-head phase 2 study against an opioid treatment in the management of short and frequent episodes of incapacitating pain (breakthrough pain) requesting immediate release opioid treatment in patients living with cancer. Expanding to three (3) immediate release oral opioids will allow for the acceleration of patient enrolment in the REBORN1© trial. ('Tetra' or the 'Company') (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that the Central Ethics Committee has approved the proposed protocol modifications allowing additional immediate release oral opioids to be used as comparators in the REBORN1© study. OTTAWA, ON, J/PRNewswire/ - Tetra Bio-Pharma Inc. QIXLEEF™ has the potential to transform the pain market, offering an alternative to prescribed opioids in the management of breakthrough pain.REBORN1© is the first of its kind proof-of-concept phase 2 study comparing a cannabinoid-based drug, QIXLEEF™, to immediate release oral opioid for the treatment of breakthrough cancer pain.

Ethics Committee approves REBORN1© protocol amendment allowing for the addition of two immediate release oral opioids to be compared against QIXLEEF™.